The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

VAMAS6  -  Vitiligo

Homo sapiens

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of VTLG


Psychiatry related information on VTLG


High impact information on VTLG


Chemical compound and disease context of VTLG


Biological context of VTLG


Anatomical context of VTLG


Associations of VTLG with chemical compounds


Physical interactions of VTLG


Regulatory relationships of VTLG

  • Based on our results we hypothesize that the low incidence for actinic damage, basal cell and squamous cell carcinoma as documented in vitiligo could well reside in a protective function of up-regulated wild-type p53 [31].
  • Analysis by reverse transcription-polymerase chain reaction (RT-PCR) and by western blotting for ET-1 and SCF unexpectedly demonstrated up-regulated expression of these cytokines in lesional vitiligo epidermis [32].
  • The average number of epidermal CD117 expressing cells followed the same pattern of decreased expression in hypopigmented mycosis fungoides as in vitiligo, whereas the levels in conventional mycosis fungoides were higher, and similar to that observed in normal skin [33].
  • The results indicate that the LYP missense R620W polymorphism may have an influence on the development of generalised vitiligo and provide further evidence for autoimmunity as an aetiological factor with respect to this disease [34].
  • It was found that epidermal homogenates from vitiligo patients expressed higher levels of COMT activity than homogenates from healthy controls [35].

Other interactions of VTLG


Analytical, diagnostic and therapeutic context of VTLG


  1. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. Ahonen, P., Myllärniemi, S., Sipilä, I., Perheentupa, J. N. Engl. J. Med. (1990) [Pubmed]
  2. Autoimmune vitiligo: detection of antibodies to melanin-producing cells. Hertz, K.C., Gazze, L.A., Kirkpatrick, C.H., Katz, S.I. N. Engl. J. Med. (1977) [Pubmed]
  3. Avian models with spontaneous autoimmune diseases. Wick, G., Andersson, L., Hala, K., Gershwin, M.E., Selmi, C., Erf, G.F., Lamont, S.J., Sgonc, R. Adv. Immunol. (2006) [Pubmed]
  4. Cutaneous immunofluorescence in primary biliary cirrhosis. Randle, H.W., Millns, J.L., Schroeter, A.L., Winkelmann, R.K. JAMA (1981) [Pubmed]
  5. Undifferentiated cell transplant techniques appear effective in treating leg ulcers, vitiligo. Skolnick, A.A. JAMA (1991) [Pubmed]
  6. Progressive vitiligo, mental retardation, facial dysmorphism, and urethral duplication without chromosomal breakage or immunodeficiency. Labrune, P., Assathiany, R., Penso, D., Odièvre, M. J. Med. Genet. (1992) [Pubmed]
  7. The Explanatory Model Interview Catalogue (EMIC). Contribution to cross-cultural research methods from a study of leprosy and mental health. Weiss, M.G., Doongaji, D.R., Siddhartha, S., Wypij, D., Pathare, S., Bhatawdekar, M., Bhave, A., Sheth, A., Fernandes, R. The British journal of psychiatry : the journal of mental science. (1992) [Pubmed]
  8. An unusual case of the Capgras syndrome. Fialkov, M.J., Robins, A.H. The British journal of psychiatry : the journal of mental science. (1978) [Pubmed]
  9. Stressful life events, social support, attachment security and alexithymia in vitiligo. A case-control study. Picardi, A., Pasquini, P., Cattaruzza, M.S., Gaetano, P., Melchi, C.F., Baliva, G., Camaioni, D., Tiago, A., Abeni, D., Biondi, M. Psychotherapy and psychosomatics. (2003) [Pubmed]
  10. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Schallreuter, K.U., Wood, J.M., Pittelkow, M.R., Gütlich, M., Lemke, K.R., Rödl, W., Swanson, N.N., Hitzemann, K., Ziegler, I. Science (1994) [Pubmed]
  11. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. Yee, C., Thompson, J.A., Roche, P., Byrd, D.R., Lee, P.P., Piepkorn, M., Kenyon, K., Davis, M.M., Riddell, S.R., Greenberg, P.D. J. Exp. Med. (2000) [Pubmed]
  12. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. Ogg, G.S., Rod Dunbar, P., Romero, P., Chen, J.L., Cerundolo, V. J. Exp. Med. (1998) [Pubmed]
  13. Extensive vitiligo after ganciclovir treatment of GvHD in a patient who had received donor T cells expressing herpes simplex virus thymidine kinase. Aubin, F., Cahn, J.Y., Ferrand, C., Angonin, R., Humbert, P., Tiberghien, P. Lancet (2000) [Pubmed]
  14. Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo. Venneker, G.T., Westerhof, W., de Vries, I.J., Drayer, N.M., Wolthers, B.G., de Waal, L.P., Bos, J.D., Asghar, S.S. J. Invest. Dermatol. (1992) [Pubmed]
  15. Red lunulae: case report and literature review. Cohen, P.R. J. Am. Acad. Dermatol. (1992) [Pubmed]
  16. Dermatitis produced by applications of monobenzone in patients with active vitiligo. Nordlund, J.J., Forget, B., Kirkwood, J., Lerner, A.B. Archives of dermatology. (1985) [Pubmed]
  17. Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis. Henderson, C.A., Ilchyshyn, A. Br. J. Dermatol. (1995) [Pubmed]
  18. Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. Arcos-Burgos, M., Parodi, E., Salgar, M., Bedoya, E., Builes, J., Jaramillo, D., Ceballos, G., Uribe, A., Rivera, N., Rivera, D., Fonseca, I., Camargo, M., Palacio, G. Hum. Genet. (2002) [Pubmed]
  19. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Nath, S.K., Majumder, P.P., Nordlund, J.J. Am. J. Hum. Genet. (1994) [Pubmed]
  20. Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Nath, S.K., Kelly, J.A., Namjou, B., Lam, T., Bruner, G.R., Scofield, R.H., Aston, C.E., Harley, J.B. Am. J. Hum. Genet. (2001) [Pubmed]
  21. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. Kemp, E.H., Waterman, E.A., Hawes, B.E., O'Neill, K., Gottumukkala, R.V., Gawkrodger, D.J., Weetman, A.P., Watson, P.F. J. Clin. Invest. (2002) [Pubmed]
  22. Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Neumeister, P., Strunk, D., Apfelbeck, U., Sill, H., Linkesch, W. Lancet (2000) [Pubmed]
  23. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Homberg, J.C., Abuaf, N., Bernard, O., Islam, S., Alvarez, F., Khalil, S.H., Poupon, R., Darnis, F., Lévy, V.G., Grippon, P. Hepatology (1987) [Pubmed]
  24. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Le Poole, I.C., van den Wijngaard, R.M., Westerhof, W., Das, P.K. Am. J. Pathol. (1996) [Pubmed]
  25. Occupational vitiligo induced by p-tert-butylphenol, a systemic disease? James, O., Mayes, R.W., Stevenson, C.J. Lancet (1977) [Pubmed]
  26. Clinical picture: leopard-like vitiligo with capecitabine. Schmid-Wendtner, M.H., Wendtner, C.M., Volkenandt, M., Heinemann, V. Lancet (2001) [Pubmed]
  27. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Gattinoni, L., Ranganathan, A., Surman, D.R., Palmer, D.C., Antony, P.A., Theoret, M.R., Heimann, D.M., Rosenberg, S.A., Restifo, N.P. Blood (2006) [Pubmed]
  28. Epidermal H(2)O(2) accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent processes? Schallreuter, K.U., Moore, J., Wood, J.M., Beazley, W.D., Peters, E.M., Marles, L.K., Behrens-Williams, S.C., Dummer, R., Blau, N., Thöny, B. J. Invest. Dermatol. (2001) [Pubmed]
  29. Demonstration of tyrosinase in the vitiligo skin of human beings by a sensitive fluorometric method as well as by 14C(U)-L-tyrosine incorporation into melanin. Husain, I., Vijayan, E., Ramaiah, A., Pasricha, J.S., Madan, N.C. J. Invest. Dermatol. (1982) [Pubmed]
  30. Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. Gottumukkala, R.V., Gavalas, N.G., Akhtar, S., Metcalfe, R.A., Gawkrodger, D.J., Haycock, J.W., Watson, P.F., Weetman, A.P., Kemp, E.H. Lab. Invest. (2006) [Pubmed]
  31. Increased epidermal functioning wild-type p53 expression in vitiligo. Schallreuter, K.U., Behrens-Williams, S., Khaliq, T.P., Picksley, S.M., Peters, E.M., Marles, L.K., Westerhof, W., Miehe, B., Fanghänel, J. Exp. Dermatol. (2003) [Pubmed]
  32. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. Kitamura, R., Tsukamoto, K., Harada, K., Shimizu, A., Shimada, S., Kobayashi, T., Imokawa, G. J. Pathol. (2004) [Pubmed]
  33. Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Singh, Z.N., Tretiakova, M.S., Shea, C.R., Petronic-Rosic, V.M. Mod. Pathol. (2006) [Pubmed]
  34. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Cantón, I., Akhtar, S., Gavalas, N.G., Gawkrodger, D.J., Blomhoff, A., Watson, P.F., Weetman, A.P., Kemp, E.H. Genes Immun. (2005) [Pubmed]
  35. Catechol-O-methyltransferase in vitiligo. Le Poole, I.C., van den Wijngaard, R.M., Smit, N.P., Oosting, J., Westerhof, W., Pavel, S. Arch. Dermatol. Res. (1994) [Pubmed]
  36. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo. Austin, L.M., Boissy, R.E. Am. J. Pathol. (1995) [Pubmed]
  37. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. Hedstrand, H., Ekwall, O., Olsson, M.J., Landgren, E., Kemp, E.H., Weetman, A.P., Perheentupa, J., Husebye, E., Gustafsson, J., Betterle, C., Kämpe, O., Rorsman, F. J. Biol. Chem. (2001) [Pubmed]
  38. A Role for Tyrosinase-Related Protein 1 in 4-tert-Butylphenol-Induced Toxicity in Melanocytes: Implications for Vitiligo. Manga, P., Sheyn, D., Yang, F., Sarangarajan, R., Boissy, R.E. Am. J. Pathol. (2006) [Pubmed]
  39. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. Mandelcorn-Monson, R.L., Shear, N.H., Yau, E., Sambhara, S., Barber, B.H., Spaner, D., DeBenedette, M.A. J. Invest. Dermatol. (2003) [Pubmed]
  40. Antibodies to normal human melanocytes in vitiligo. Naughton, G.K., Eisinger, M., Bystryn, J.C. J. Exp. Med. (1983) [Pubmed]
  41. Melanocyte transplantation in vitiligo. Olsson, M.J., Juhlin, L. Lancet (1992) [Pubmed]
  42. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. Luiten, R.M., Kueter, E.W., Mooi, W., Gallee, M.P., Rankin, E.M., Gerritsen, W.R., Clift, S.M., Nooijen, W.J., Weder, P., van de Kasteele, W.F., Sein, J., van den Berk, P.C., Nieweg, O.E., Berns, A.M., Spits, H., de Gast, G.C. J. Clin. Oncol. (2005) [Pubmed]
WikiGenes - Universities